{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T04:02:05Z","timestamp":1780372925790,"version":"3.54.1"},"reference-count":47,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals, Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lipidjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.jacl.2016.02.003","type":"journal-article","created":{"date-parts":[[2016,2,20]],"date-time":"2016-02-20T07:47:29Z","timestamp":1455954449000},"page":"627-634","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Alirocumab in patients with heterozygous familial hypercholesterolemia undergoing lipoprotein apheresis: Rationale and design of the ODYSSEY ESCAPE trial"],"prefix":"10.1016","volume":"10","author":[{"given":"Patrick M.","family":"Moriarty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus G.","family":"Parhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan P.","family":"Babirak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil","family":"deGoma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Barton","family":"Duell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Hohenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Ramlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9858-2832","authenticated-orcid":false,"given":"Vinaya","family":"Simha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Steinhagen-Thiessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Vogt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berndt","family":"von Stritzky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunling","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5491-1032","authenticated-orcid":false,"given":"Garen","family":"Manvelian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2016.02.003_bib1","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1210\/jc.2012-1563","article-title":"Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication","volume":"97","author":"Benn","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacl.2016.02.003_bib2","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.atherosclerosis.2013.12.020","article-title":"Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers","volume":"233","author":"Besseling","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2016.02.003_bib3","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.ahj.2014.09.001","article-title":"Reducing the burden of disease and death from familial hypercholesterolemia: a call to action","volume":"168","author":"Knowles","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacl.2016.02.003_bib4","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nature13917","article-title":"Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction","volume":"518","author":"Do","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jacl.2016.02.003_bib5","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.jacl.2011.03.452","article-title":"Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia","volume":"5","author":"Hopkins","year":"2011","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2016.02.003_bib6","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacl.2011.04.003","article-title":"Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia","volume":"5","author":"Goldberg","year":"2011","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2016.02.003_bib7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.atherosclerosis.2003.11.010","article-title":"Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia","volume":"173","author":"Civeira","year":"2004","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2016.02.003_bib8","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"32","author":"Reiner","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2016.02.003_bib9","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/S0140-6736(69)90930-1","article-title":"Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states","volume":"2","author":"Slack","year":"1969","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2016.02.003_bib10","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1161\/01.CIR.49.3.476","article-title":"Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia","volume":"49","author":"Stone","year":"1974","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2016.02.003_bib11","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1136\/bmj.303.6807.893","article-title":"Risk of fatal coronary heart disease in familial hypercholesterolaemia","volume":"303","year":"1991","journal-title":"BMJ"},{"key":"10.1016\/j.jacl.2016.02.003_bib12","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2016.02.003_bib13","first-page":"2625","article-title":"Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study","volume":"29","author":"Neil","year":"2008","journal-title":"Eur\u00a0Heart J"},{"key":"10.1016\/j.jacl.2016.02.003_bib14","doi-asserted-by":"crossref","first-page":"667","DOI":"10.5551\/jat.4143","article-title":"Impact of statin treatment on the clinical fate of heterozygous familial hypercholesterolemia","volume":"17","author":"Harada-Shiba","year":"2010","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.jacl.2016.02.003_bib15","doi-asserted-by":"crossref","first-page":"e9220","DOI":"10.1371\/journal.pone.0009220","article-title":"Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal","volume":"5","author":"Huijgen","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.jacl.2016.02.003_bib16","doi-asserted-by":"crossref","first-page":"a2423","DOI":"10.1136\/bmj.a2423","article-title":"Efficacy of statins in familial hypercholesterolaemia: a long term cohort study","volume":"337","author":"Versmissen","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.jacl.2016.02.003_bib17","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/ncpcardio1456","article-title":"Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events","volume":"6","author":"Jaeger","year":"2009","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"10.1016\/j.jacl.2016.02.003_bib18","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jacl.2010.08.015","article-title":"Novel therapies and new targets of treatment for familial hypercholesterolemia","volume":"4","author":"Goldberg","year":"2010","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2016.02.003_bib19","doi-asserted-by":"crossref","first-page":"139","DOI":"10.18553\/jmcp.2013.19.2.139","article-title":"Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia","volume":"19","author":"Robinson","year":"2013","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.jacl.2016.02.003_bib20","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0021-9150(00)00371-3","article-title":"The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels","volume":"152","author":"Kroon","year":"2000","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2016.02.003_bib21","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ijcard.2014.06.049","article-title":"Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized phase 3 trial","volume":"176","author":"Roth","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacl.2016.02.003_bib22","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/eurheartj\/ehv028","article-title":"Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial","volume":"36","author":"Cannon","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2016.02.003_bib23","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1210\/jc.2015-1520","article-title":"Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial","volume":"100","author":"Bays","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacl.2016.02.003_bib24","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.ahj.2015.03.004","article-title":"Efficacy and safety of the proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study","volume":"169","author":"Kereiakes","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacl.2016.02.003_bib25","first-page":"2996","article-title":"ODYSSEY FH I and FH\u00a0II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia","volume":"36","author":"Kastelein","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2016.02.003_bib26","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1056\/NEJMoa1201832","article-title":"Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia","volume":"367","author":"Roth","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2016.02.003_bib27","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/j.jacc.2012.03.007","article-title":"Safety and efficacy of a monoclonal antibody to proprotein\u00a0convertase subtilisin\/kexin type 9 serine protease, SAR236553\/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy","volume":"59","author":"McKenney","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2016.02.003_bib28","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2016.02.003_bib29","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(12)60771-5","volume":"380","author":"Stein","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2016.02.003_bib30","volume":"16","year":"1998","journal-title":"Familial Hypercholesterolemia (FH). Report of a Second WHO Consultation"},{"key":"10.1016\/j.jacl.2016.02.003_bib31","first-page":"3478","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur\u00a0Heart J"},{"key":"10.1016\/j.jacl.2016.02.003_bib32","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1161\/01.ATV.20.2.522","article-title":"Lipoprotein(a) in homozygous familial hypercholesterolemia","volume":"20","author":"Kraft","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2016.02.003_bib33","series-title":"The Well-Being Questionnaire. Handbook of Psychology and Diabetes: A Guide to Psychological Measurement in Diabetes Research and Practice","first-page":"89","author":"Bradley","year":"1994"},{"key":"10.1016\/j.jacl.2016.02.003_bib34","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1053\/meta.2002.34016","article-title":"Atorvastatin in low-density lipoprotein apheresis-treated patients with homozygous and heterozygous familial hypercholesterolemia","volume":"51","author":"Goldammer","year":"2002","journal-title":"Metabolism"},{"key":"10.1016\/j.jacl.2016.02.003_bib35","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.jacl.2011.04.001","article-title":"Management of familial hypercholesterolemias in adult patients: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia","volume":"5","author":"Ito","year":"2011","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2016.02.003_bib36","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s11936-006-0049-z","article-title":"LDL-apheresis therapy","volume":"8","author":"Moriarty","year":"2006","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"10.1016\/j.jacl.2016.02.003_bib37","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2165\/11594970-000000000-00000","article-title":"Defining the role of lipoprotein apheresis in the management of familial hypercholesterolemia","volume":"11","author":"Lee","year":"2011","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.jacl.2016.02.003_bib38","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0002-9149(97)00947-8","article-title":"Long-term effects of low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. Liposorber Study Group","volume":"81","author":"Gordon","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2016.02.003_bib39","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1081\/JDI-200031742","article-title":"Therapeutic apheresis of immune diseases in nephrology department","volume":"26","author":"Visvardis","year":"2004","journal-title":"Ren Fail"},{"key":"10.1016\/j.jacl.2016.02.003_bib40","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1177\/039139889501801207","article-title":"Four years' treatment efficacy of patients with severe hyperlipidemia. Lipid lowering drugs versus LDL-apheresis","volume":"18","author":"Schiel","year":"1995","journal-title":"Int J Artif Organs"},{"key":"10.1016\/j.jacl.2016.02.003_bib41","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.atherosclerosissup.2015.02.035","article-title":"Mental symptoms and quality of life in lipoprotein apheresis patients in comparison to hemodialysis patients, platelet donors and normal population","volume":"18","author":"Stasiewski","year":"2015","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.jacl.2016.02.003_bib42","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S0140-6736(95)92961-4","article-title":"Familial Hypercholesterolaemia Regression Study: a randomised trial of low-density-lipoprotein apheresis","volume":"345","author":"Thompson","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2016.02.003_bib43","first-page":"864317","article-title":"Usefulness of lipid apheresis in the treatment of familial hypercholesterolemia","volume":"2014","author":"Lui","year":"2014","journal-title":"J\u00a0Lipids"},{"key":"10.1016\/j.jacl.2016.02.003_bib44","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2016.02.003_bib45","series-title":"Efficacy and Safety of Combining Alirocumab With Atorvastatin or Rosuvastatin Versus Adding Ezetimibe, Doubling Statin Dose or Switching Statin Therapy in High Cardiovascular Risk Patients: ODYSSEY OPTIONS I and II","author":"Bays","year":"2014"},{"key":"10.1016\/j.jacl.2016.02.003_bib46","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ahj.2014.07.028","article-title":"Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design\u00a0of the ODYSSEY\u00a0outcomes trial","volume":"168","author":"Schwartz","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacl.2016.02.003_bib47","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jacc.2014.01.063","article-title":"Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation","volume":"63","author":"Alonso","year":"2014","journal-title":"J Am Coll Cardiol"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287415300684?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287415300684?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T18:24:39Z","timestamp":1654367079000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287415300684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S1933287415300684"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2016.02.003","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alirocumab in patients with heterozygous familial hypercholesterolemia undergoing lipoprotein apheresis: Rationale and design of the ODYSSEY ESCAPE trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2016.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 National Lipid Association. All rights reserved.","name":"copyright","label":"Copyright"}]}}